As of 2025-05-15, the EV/EBITDA ratio of ReShape Lifesciences Inc (RSLS) is -13.25. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RSLS's latest enterprise value is 85.47 mil USD. RSLS's TTM EBITDA according to its financial statements is -6.45 mil USD. Dividing these 2 quantities gives us the above RSLS EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 5.4x - 7.1x | 6.7x |
| Forward P/E multiples | 6.1x - 16.2x | 7.4x |
| Fair Price | (2.79) - (3.26) | (3.23) |
| Upside | -146.1% - -154.0% | -153.4% |
| Date | EV/EBITDA |
| 2025-04-10 | -1.26 |
| 2025-04-09 | -0.77 |
| 2025-04-08 | -0.85 |
| 2025-04-07 | -0.97 |
| 2025-04-04 | -1.02 |
| 2025-04-03 | -0.85 |
| 2025-04-02 | -1.00 |
| 2025-04-01 | -3.49 |
| 2025-03-31 | -0.81 |
| 2025-03-28 | -0.86 |
| 2025-03-27 | -0.98 |
| 2025-03-26 | -1.05 |
| 2025-03-25 | -1.16 |
| 2025-03-24 | -1.44 |
| 2025-03-21 | -1.47 |
| 2025-03-20 | -1.54 |
| 2025-03-19 | -1.40 |
| 2025-03-18 | -1.42 |
| 2025-03-17 | -1.40 |
| 2025-03-14 | -1.41 |
| 2025-03-13 | -1.41 |
| 2025-03-12 | -1.48 |
| 2025-03-11 | -1.53 |
| 2025-03-10 | -1.62 |
| 2025-03-07 | -2.00 |
| 2025-03-06 | -2.10 |
| 2025-03-05 | -2.18 |
| 2025-03-04 | -2.23 |
| 2025-03-03 | -2.40 |
| 2025-02-28 | -2.27 |
| 2025-02-27 | -2.42 |
| 2025-02-26 | -2.55 |
| 2025-02-25 | -2.53 |
| 2025-02-24 | -2.99 |
| 2025-02-21 | -2.47 |
| 2025-02-20 | -2.71 |
| 2025-02-19 | -2.99 |
| 2025-02-18 | -2.38 |
| 2025-02-14 | -5.11 |
| 2025-02-13 | -5.57 |
| 2025-02-12 | -6.11 |
| 2025-02-11 | -5.93 |
| 2025-02-10 | -6.16 |
| 2025-02-07 | -6.21 |
| 2025-02-06 | -6.74 |
| 2025-02-05 | -7.29 |
| 2025-02-04 | -7.82 |
| 2025-02-03 | -7.78 |
| 2025-01-31 | -8.26 |
| 2025-01-30 | -8.26 |